A close-up of a blue text

Description automatically generated

**Clarification Log 4th March 2025 Version 3**

|  |  |  |  |
| --- | --- | --- | --- |
| Date Received | Clarification Question | NEYPPC Clarification Response | Response Date |
| 11/02/2025 | A supplier has highlighted an issue with the “Document 6b Product Specification Response (Form B)” and the naming protocol and that it does not allow for separate identification of documents that pertain to each products lot where provided. | We would like you to provide product specific **zip folder(s)** that are named with the product lot and product name for example:  Lot 1\_Ajmaline 50mg\_10ml\_Injection\_FormB  Where you are providing multiple alternative offers for one product lot, please follow zip folder name with “(1)”, or “(2)” for example:  Lot 1\_Ajmaline 50mg\_10ml\_Injection\_FormB (1)  Lot 1\_Ajmaline 50mg\_10ml\_Injection\_FormB (2)  Contained within each product lot zip folder should be:   * Document 6b Product Specification Response (Form B) * Supporting documents named following the naming protocol stipulated in form B | 11/02/2025 |
| 27/02/2025 | Supplier has raised a query regarding sections 24 to 27 of the Document 6b Product Specification Response (Form B) and how to document where products do not have a package leaflet or PIL or need translated documents. | Suppliers are able to clarify with a statement in the Document 6b Product Specification Response (Form B) against the identified sections to make clear as to which documents are available for each product lot. | 27/02/25 |
| 03/03/2025 | Supplier has asked if Lot 30 Patent blue 50mg/2ml solution for injection if it is a pre-filled syringe or an ampoule as the pharmaceutical form and would both forms be acceptable. | Please refer to Document 9 Commercial Schedule (Introduction) Note 8 Offer: Offerors are able to submit a maximum of **3 alternative proposals** against each product lot where applicable.  Please refer to Document 2 "Terms of Offer" point 11. NB “Alternative proposals” may be either pre-filled syringes or ampoules as long as all licensed in a trusted country as set out in Document 8 Tender Response (Component 1) specification point A3 | 04/03/2025 |
| 03/03/2025 | Supplier has asked about Latex status evidence and how this can be provided when they receive this from the supplier/manufacturer and whether the statement can be directly added to the Document 6b Product Specification Response Form (Form B) or if they are able to provide a separate document following the naming protocol. | **Within Document 6b Product Specification Response Form (Form B) states against Reference point 19 (row27)** *Do not embed documents: please provide as separate document(s) using the naming protocol [Supplier Name\_Doc6\_Form B\_19]*  **NEYPPC will accept the following methods of evidence**  Where the evidence exists as a document, please follow guidance above. However, if the evidence is given as a text statement, this can be provided as text only in cell C27 | 04/03/2025 |